NewAmsterdam Pharma Company N.V. NAMS 深 沪
已收盘 12-19 16:00:00 美东时间
35.09
+1.190
+3.51%
华盛通- 最 高42.00
- 今 开34.27
- 成交量 75.34万股
- 最 低 32.85
- 昨 收 33.90
- 总市值 0
- 52周最高 42.00
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 14.06
- 委 比 82.00%
- 总股本 --
- 历史最高 42.00
- 量 比 0.80
- 振 幅 26.99%
- 历史最低 1.10
- 每 手 1
- 风险率 6.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
New Amsterdam Pharma's Phase 3 BROADWAY trial shows obicetrapib, a CETP inhibitor, significantly reduces Alzheimer's biomarker p-tau217 in both full ITT population and ApoE4 carriers, supporting its potential in AD prevention.
06-09 11:00
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NewAmsterdam Pharma will host an R&D Day event on June 11, 2025, in New York City, featuring key executives. The event will discuss their late-stage clinical program for obicetrapib, an LDL-lowering CETP inhibitor, including Phase 3 trial results and commercialization efforts. A live webcast and replay will be available on their investor relations website.
06-05 12:00
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
NewAmsterdam Pharma to host investor presentations at William Blair, Jefferies, and Goldman Sachs conferences
05-27 12:00
Expert Ratings For NewAmsterdam Pharma
4 analysts have shared their evaluations of NewAmsterdam Pharma (NASDAQ:NAMS) d...
2024-09-23 21:00
RBC Capital Reiterates Outperform on NewAmsterdam Pharma, Maintains $31 Price Target
RBC Capital analyst Leonid Timashev reiterates NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform and maintains $31 price target.
2024-09-06 00:00
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside
Needham has initiated coverage on NewAmsterdam Pharma Company N.V (NASDAQ:NAMS), a clinical-stage biopharma developing obicetrapib, an orally-dosed CETP inhibitor for lowering cholesterol. In July, NewAmsterdam Pharma released topline data from the Phase 3 BROOKLYN trial, the first of four studies i...
2024-08-29 01:33
--Needham Initiates NewAmsterdam Pharma at Buy With $36 Price Target
07:30 AM EDT, 08/28/2024 (MT Newswires) --
2024-08-28 19:30
Needham Initiates Coverage On NewAmsterdam Pharma with Buy Rating, Announces Price Target of $36
Needham analyst Serge Belanger initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating and announces Price Target of $36.
2024-08-28 18:46
